HDACs have been Implicated in Promoting Tumori-Genesis Mainly by Silencing Tumor Suppressor Genes and Apoptosis Inducers : A Part from The Book Chapter : Unveiling the Potential of Combined BET and HDAC Inhibition in MYC-driven Medulloblastoma Treatment: A Promising Epigenetic Approach

HDACs have been implicated in promoting tumori-genesis mainly by silencing tumor suppressor genes and apoptosis inducers. As HDACs are frequently over- expressed in cancers including MB, they have been recognized as promising therapeutic targets, and several pharmacologically distinct HDAC inhibitors have been developed. Various HDAC inhibitors, such as panobinostat and vorinostat, have shown potent efficacy against MB in preclinical studies. More than a dozen HDAC inhibitors are currently being evaluated in the clinic and/or clinical trials. While the results of preclinical studies are encouraging, early clinical trials of HDAC inhibitors have only shown a limited efficacy in patients with advanced tumors. Therefore, it is important to explore epigenetic-based drug combination strate- gies to improve efficacy against tumors in general, and to identify promising approaches against MB in particular.

Author(s) Details:

Matthew J. Kling,
Department of Oral Biology, Creighton University, School of Dentistry, Omaha, NE 68102, USA and Child Health Research Institute, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Varun Kesherwani,
Child Health Research Institute, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Nitish K. Mishra,
Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Gracey Alexander,
Department of Pediatrics, Hematology/Oncology Division, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Erin M. McIntyre,
Department of Pediatrics, Hematology/Oncology Division, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Sutapa Ray,
Child Health Research Institute, University of Nebraska Medical Center, Omaha, NE 68198, USA and Department of Pediatrics, Hematology/Oncology Division, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Kishore B. Challagundla,
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Shantaram S. Joshi,
Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Don W. Coulter,
Child Health Research Institute, University of Nebraska Medical Center, Omaha, NE 68198, USA and Department of Pediatrics, Hematology/Oncology Division, University of Nebraska Medical Center, Omaha, NE 68198, USA.

Nagendra K. Chaturvedi,
Child Health Research Institute, University of Nebraska Medical Center, Omaha, NE 68198, USA and Department of Pediatrics, Hematology/Oncology Division, University of Nebraska Medical Center, Omaha, NE 68198, USA and Department of Pediatrics, Hematology and Oncology Division, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE 68198, USA.

To Read the Complete Chapter See Here

Leave a Reply